Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Stem cell success against motor neurone disease in mice

07 January 2013

By Dr Tamara Hirsch

Appeared in BioNews 687

Neural stem cells were shown to be effective against amyotrophic lateral sclerosis (ALS), or motor neurone disease, in 11 independent studies on mice with the disease. In the research, stem cell injections into the rodents' spinal cords slowed disease onset and progression, improved motor function, and significantly prolonged survival.

The studies are grouped together in a meta-analysis published in Science Translational Medicine.

Dr Ted Teng, associate professor of surgery at Brigham and Women's Hospital in the USA, and one of the principal investigators, stressed that the technique was 'not a cure for ALS', but added that the research 'shows the potential that mechanisms used by neural stem cells in our study have for improving an ALS patient's quality of life and length of life'.

Neural stem cells normally develop into the specialised cells of the nervous system. The 11 studies grouped in this paper were performed over the last ten years. Professor Evan Snyder of the Burnham Institute in the USA, one of the study group leaders, told KUHF FM: 'In the early days we thought, "well, stem cells should simply replace these dying motor neurones"'.

But the benefits in the mouse experiments were shown to come from other mechanisms. Professor Snyder told KUHF FM that the stem cells appear to work by two methods: 'A: protecting [healthy] neurones and their connections from dying. B: crowding out or suppressing the cells that may be causing the disease and also getting rid of a lot of inflammation, making growth factors, making the cells that were there actually healthier'.

'Cell replacement plays a surprisingly small role' in the benefits afforded by neural stem cells, said Professor Snyder.

And the benefits were considerable. In the study performed by Professor Snyder's team the ALS mice lived three to four times longer than their untreated counterparts.

However, whether such improvement will translate to patients in a clinical situation remains to be seen. A clinical trial to test neural stem cells in ALS patients began at the end of 2011. Initial results were encouraging (reported in BioNews 651) but the study is still in its earliest phase.

Currently there is no cure for ALS and little effective treatment. ALS is a progressive, late-onset neurodegenerative disorder where the brain's ability to relay signals to the muscles is compromised. This leads to loss of voluntary muscle movement, and ultimately paralysis and respiratory failure. ALS affects around one in every 50,000 people.

SOURCES & REFERENCES
Harvard Gazette | 02 January 2013
 
Science Translational Medicine | 19 December 2012
 
KUHF FM | 21 December 2012
 
EurekAlert! (press release) | 19 December 2012
 
ScienceDaily (press release) | 19 December 2012
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

05 October 2015 - by Hannah Somers 
Reactivation of an ancient virus embedded in the human genome may trigger the onset of motor neurone disease...
13 October 2014 - by Rhys Baker 
The US Food and Drug Administration (FDA) has awarded 'fast-track' status to a potential stem cell therapy for Amyotrophic Lateral Sclerosis (ALS), or motor neurone disease...
19 May 2014 - by Alice Plein 
Mice with a viral form of multiple sclerosis are able to walk again after receiving a transplant of human stem cells, scientists report...
04 March 2013 - by Dr Greg Ball 
Mouse embryonic stem cells are being transported to the International Space Station (ISS) to investigate the impact of long-term space flight on human health....
11 February 2013 - by Richard Fadok 
Brain cells engineered from human skin tissue have successfully treated laboratory mice with a deadly nerve disorder with similarities to multiple sclerosis...

02 April 2012 - by Dr Linda Wijlaars 
A clinical trial to test the safety of a stem cell treatment for amyotrophic lateral sclerosis, the most common form of motor neurone disease, suggests that the new therapy is safe and well-tolerated. Encouragingly, one of the 12 patients participating in the study showed some improvement, although the trial was not designed to test the treatment's efficacy...
28 November 2011 - by Dr Marianne Kennedy 
On 18 November, Richard Grosjean became the first patient to receive a pioneering stem cell treatment in the upper part of the spinal cord. His procedure is part of an ongoing US-based clinical trial aimed at assessing the safety of injecting neural stem cells taken from eight-week-old fetuses into the spinal cords of patients with amyotrophic lateral sclerosis (ALS)...
28 September 2009 - by Dr Marianne Kennedy 
The US Food and Drug Administration (FDA) has granted approval to NeuralStem Inc., a Maryland-based biotherapeutics company, to conduct the first human trial using neural stem cells for treatment of amyotrophic lateral sclerosis (ALS). ALS is a type of motor neuron disease often referred to as 'Lou Gehrig's' and 'Maladie de Charcot'. The late-onset condition, of unknown cause, affects approximately two in 100,000 people, including the UK physicist Stephen Hawking and US rock gui...
04 August 2008 - by Dr Rachael Panizzo 
Scientists at the Harvard Stem Cell Institute and the Columbia University Medical Center in the US have reprogrammed the skin cells of two patients with amyloid lateral sclerosis (ALS), making induced pluripotent stem (iPS) cells. The stem cells were then used to generate motor neurons - the nerve...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation